JAK1 and anaplastic large cell lymphoma: Recent findings showed proliferation and survival programs in ALCL-ALKneg and PTCL-NOS patients are driven by the presence of activating mutations on STAT3 or mutations involving other genes that secondarily activate STAT3 such as JAK1 or kinase fusions22.